Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor

• by Yanhong Jia, Xue Wang, Yuanxiang Liu, Zigang Xu, Bin Zhang

• July 16, 2026

FDA Approves Less Frequent Lebrikizumab Dosing

Approval adds an every-8-week maintenance option for eligible patients with moderate-to-severe atopic dermatitis.

• by Kathryn Wighton

• June 10, 2026

• 2 min

FDA Approves New Oral Option for Plaque Psoriasis

Phase 3 data showed high skin clearance rates and adverse event rates similar to placebo through week 16 with once-daily icotrokinra.

• by Kathryn Wighton

• March 18, 2026

• 2 min

Smartwatch May Track AD Status in Children

Wearable-derived scratching measures align with disease activity and short-term treatment response in pediatric patients with atopic dermatitis.

• by Andrea Surnit

• May 5, 2026

• 3 min